Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945695 | 0.94 | — | — | |
| Acetic Acid SCHEMBL9778982 | 0.88 | MEN1 (0.39) | MEN1LMNAKMT2ASPHK2SPHK1 | |
| SCHEMBL13004398 | 0.87 | — | — | |
| SCHEMBL2310066 | 0.81 | SPHK2 (0.33) | SPHK2SPHK1 | |
| SCHEMBL25764174 | 0.79 | SPHK2 (0.35) | MEN1LMNAKMT2ASPHK2SPHK1 | |
| SCHEMBL21675825 | 0.76 | MEN1 (0.38) | MEN1LMNAKMT2ASPHK2SPHK1 | |
| SCHEMBL1440695 | 0.74 | — | — | |
| SCHEMBL15648240 | 0.73 | — | — | |
| SCHEMBL14981017 | 0.73 | MEN1 (0.53) | MEN1LMNAKMT2AKDM4EPOLB | |
| Hydrochloric Acid SCHEMBL534428 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9309422-B2 | Ink set for inkjet recording and image forming method | FUJIFILM CORPORATION (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9044512-B2 | Amino alcohol cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140323548-A1 | NOVEL AMINO ALCOHOL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2014-10-30 | — | — | US | disclosed |
| US-8802863-B2 | Amino alcohol cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8721035-B2 | Image forming method | FUJIFILM CORPORATION (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20140017302-A1 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CEVC GREGOR (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130150625-A1 | Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-06-13 | — | — | US | disclosed |
| EP-1899330-B9 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INT (DE) | 2011-11-09 | — | — | EP | disclosed |
| EP-1899330-B1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INT (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| EP-1899330-A1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | Boehringer Ingelheim International GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007003536-A1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
| US-4999369-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1991-03-12 | — | — | US | disclosed |
| US-4910218-A | With a hydroxy containing secondary amine group | BURROUGHS WELLCOME CO. (US) | 1990-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140017302-A1 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CD68, CHMP4B, ANXA5 | MEN1 1923/4885LMNA 1510/4885KMT2A 4455/4885 |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GNMT | MEN1 691/4885LMNA 2509/4885KMT2A 2973/4885 |
| US-20130150625-A1 | Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery | CETP, SLC7A5, NPC1L1 | MEN1 2971/4885LMNA 1010/4885KMT2A 1087/4885 |
| US-20140323548-A1 | NOVEL AMINO ALCOHOL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | CETP, SLC7A5, NPC1L1 | MEN1 2971/4885LMNA 1010/4885KMT2A 1087/4885 |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | MEN1 1229/4885LMNA 2832/4885KMT2A 2883/4885 |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | MEN1 1229/4885LMNA 2832/4885KMT2A 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.